Major changes in U.S. patent law are having an impact on the value of patents. The Leahy-Smith America
Invents Act (AIA) introduced numerous changes to U.S. patent law including the switch to a first to file patent system
from a first to invent patent system. New proceedings at the U.S. Patent and Trademark Office to challenge the grant of
issued patents have produced quick results and emerging trends. Recent U.S. Supreme Court decisions have changed the
threshold determination of patentability under 35 U.S.C. § 101, altering the patentability standards for biotech/pharma
inventions, as well as computer/business method inventions. In Europe, the framework for an emerging unitary patent
system, expected to be implemented by mid-2016, will add complexity to strategic patent planning for that region. This
article will review these changes, discuss trends and provide strategies to build a patent portfolio with valid and
enforceable patent claims as a foundation to withstand patentability and validity challenges.
Keywords: America Invents Act (AIA), Biotech/pharma, European unitary patent, Intellectual property (IP), Inventions,
patents, Patent trial and appeal board (PTAB), Patentability.
Rights & PermissionsPrintExport